Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Apr 14, 2011

Premium

Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid

Patent Number: 7,923,547

Filed: Aug. 4, 2006

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent's abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid ... capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”


Title: RNA Interference-Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Chemically Modified Short Interfering Nucleic Acid

Patent Number: 7,923,549

Filed: Jan. 7, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference using small nucleic acid molecules ... [as well as] methods used to modulate the expression of interleukin and/or interleukin receptor genes.”


Title: Interfering RNA Delivery System and Uses Thereof

Application Number: 20110082092

Filed: Dec. 14, 2010

Inventor: Jon Chatterton, Alcon

“The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule,” according to the patent application's abstract. “The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.”


Title: Cancer-Testis Gene Silencing and Uses Thereof

Application Number: 20110082185

Filed: Sept. 16, 2008

Lead Inventor: Otavia Caballero, Ludwig Institute for Cancer Research

“The invention relates to methods, formulations, and kits useful for inhibiting cancer cell viability, invasion, or migration,” the patent application's abstract states.


Title: Compositions for Inhibiting Gene Expression and Uses Thereof

Application Number: 20110082186

Filed: Aug. 26, 2010

Lead Inventor: Sudhir Agrawal, Idera Pharmaceuticals

“The inventors have examined the means for providing more efficacious gene expression-blocking compounds,” the patent application's abstract states. “The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression-blocking molecules. These features include the presence of multiple 3' ends and a linker at the 5' ends. … These features improve the efficacy of the gene expression-blocking compounds in a manner that decreases the compound's biologic instability. … This effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.”